Korean J Hematol.  2007 Dec;42(4):335-342. 10.5045/kjh.2007.42.4.335.

Treatment Outcomes and Toxicities of ABVD Combination Chemotherapy Compared with CVPP in Hodgkin's Disease

• Choi YS
• Kim BS
• Seo HY
• Sung HJ
• Park KH
• Choi IK
• Kim SJ
• Oh SC
• Seo JH
• Choi CW
• Shin SW
• Kim YH
• Kim JS

• KMID: 2252218
• DOI: http://doi.org/10.5045/kjh.2007.42.4.335

Abstract

BACKGROUND: We retrospectively evaluated the treatment outcomes and toxicities of Hodgkin's disease (HD) patients treated by ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) combination chemotherapy, and compared them with those of a historical group treated with a CVPP (cyclophosphamide, vinblastine, procarbazine, and prednisone) regimen.
METHODS
The medical records of patients who had been diagnosed with HD histologically and treated by either ABVD or CVPP from 1997 to 2006 at the Korea University Medical Center were retrospectively reviewed.
RESULTS
Thirty patients were eligible. Nineteen patients received ABVD and eleven patients were treated with CVPP. The response rates for ABVD and CVPP were 84.21% and 54.55%, respectively. Median overall survival was 43.17 months for ABVD and 43.27 months for CVPP (P=.570). Median event-free survival was 39.03 months for ABVD and 16.73 months for CVPP (P=.088). There was no significant difference in median survival or in event-free survival between the two regimens. Hematologic toxicities were significantly more common in the CVPP group than in the ABVD group. Grade 3 or 4 neutropenia was observed in 72.72% of the CVPP group and in 36.84% of the ABVD group (P=.050).
CONCLUSION
ABVD for HD showed significantly lower hematologic toxicities and moderately better treatment outcomes than did CVPP.

Keyword

Hodgkin's disease; Chemotherapy; Toxicity

MeSH Terms

Academic Medical Centers
Bleomycin
Disease-Free Survival
Drug Therapy
Drug Therapy, Combination*
Hodgkin Disease*
Humans
Korea
Medical Records
Neutropenia
Procarbazine
Retrospective Studies
Vinblastine
Bleomycin
Procarbazine
Vinblastine